Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Those rehired by the Trump administration include at least 10 FDA staffers responsible for reviewing the safety of new food ...

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

The reversal is the latest example of President Donald Trump and billionaire Elon Musk’s chaotic approach to cost-cutting, ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.